Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product Type (Instruments, Reagents & Consumables) by Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, Others), by End-user (Hospitals & Clinic

Global Thrombosis and Hemostasis Biomarkers Market Size study, by Product Type (Instruments, Reagents & Consumables) by Application (Deep Vein Thrombosis, Pulmonary Embolism, Disseminated Intravascular Coagulation, Others), by End-user (Hospitals & Clinics, Diagnostic Laboratories, Others) and Regional Forecasts 2024-2032

Global Thrombosis and Hemostasis Biomarkers Market is valued at approximately USD 5.31 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 5.9% over the forecast period 2024-2032. Thrombosis and hemostasis biomarkers are laboratory parameters derived from the components of the hemostatic system, such as von Willebrand factor (vWF), fibrinogen, D-dimer, and others. These biomarkers are instrumental in detecting certain diseases or their pathophysiological effects and have numerous applications in clinical practice. They offer significant benefits, including the risk estimation and diagnosis of venous thromboembolism (VTE) and other conditions, prediction of thrombotic events in patients with lymphoma, response to chemotherapy in patients with pancreatic cancer, and enhanced patient management.

The growth of the thrombosis and hemostasis biomarkers market is highly attributed to the increased risk of venous thromboembolism (VTE). The risk of VTE is associated with various clinical conditions such as cardiovascular, cerebrovascular, and malignant disorders. In addition, the risk increases with major or minor injuries and obesity. For instance, according to the American Heart Association, Inc. in November 2023, obese individuals have an increased risk of VTE, and the higher the risk becomes as the weight increases. Biomarkers such as D-dimer, fibrinogen, and factor VIII are used to predict the risk of VTE and monitor treatment response. This is expected to significantly boost the adoption of biomarker products, propelling the market growth during the forecast timeframe. Moreover, the growing research initiatives and funding and increasing adoption of biomarkers in clinical practice present various lucrative opportunities over the forecast years. However, the high cost and stringent regulations as well as limitations associated with biomarker use are challenging the market growth throughout the forecast period of 2024-2032.

The key regions considered for the Global Thrombosis and Hemostasis Biomarkers Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is a dominating region in the Global Thrombosis and Hemostasis Biomarkers Market in terms of revenue. The market growth in the area is being attributed to factors including the presence of a highly developed healthcare infrastructure, significant investments in research and development, and the widespread adoption of advanced diagnostic technologies. The United States leads the market due to a high prevalence of cardiovascular diseases and blood disorders, as well as strong collaborations between academic institutions and industry players to develop innovative diagnostic solutions. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising healthcare expenditures, increasing prevalence of thrombotic disorders, and a growing awareness of the importance of early diagnosis and treatment. Countries such as China, India, and Japan are experiencing significant market expansion due to the increasing burden of lifestyle-related diseases, expanding middle-class populations with improved access to healthcare, and government initiatives aimed at enhancing healthcare quality and accessibility.

Major market player included in this report are:

F. Hoffmann-La Roche Ltd

BioMedica Diagnostics

Siemens Healthcare Private Limited

Abbott

HORIBA Medical

BIOMÉRIEUX

QuidelOrtho Corporation

Stago Group

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Beckman Coulter, Inc.

Sysmex Corporation

Enzo Biochem, Inc.

Diazyme Laboratories, Inc.

Agilent Technologies, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product Type:

Instruments

Reagents & Consumables

By Application:

Deep Vein Thrombosis (DVT)

Pulmonary Embolism (PE)

Disseminated Intravascular Coagulation (DIC)

Others

By End-user:

Hospitals & Clinics

Diagnostic Laboratories

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.